🔗 Share this article

The recently developed medications for gonorrhoea in many years are being described as a "major milestone" in the battle against superbug strains of the bacteria, according to researchers.

A Global Challenge

The sexually transmitted infection are on the rise worldwide, with data suggesting more than 82 million instances per year. Notably increased rates are observed in the African continent and nations within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. In England, cases have hit a all-time high, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an important and timely step in the reality of growing infection rates, the spread of superbugs and the very limited therapeutic options currently available.”

Medical experts are particularly alarmed about the surge in antibiotic-resistant strains. The World Health Organization has classified it as a "high-priority threat". Ongoing monitoring revealed that resistance to primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Receive Approval

One new antibiotic, also known as a brand name, was authorized by the American regulatory agency in December for treating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Experts believe that specific application of this new drug will help slow the emergence of superbugs.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, also received approval in close succession. This medication, which is employed against urinary tract infections, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin emerged from a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to develop it.

“This authorization represents a significant shift in the therapy of superbug gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Clinical Trial Results and Global Access

As per results released by a major medical journal, the new drug successfully treated more than 90% of uncomplicated infections. This places it at an similar efficacy with the existing first-line therapy, which involves a dual-drug approach. The trial involved hundreds of participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, GARDP has the rights to make available and distribute the drug in a wide range of developing nations.

Medical professionals treating patients have expressed hope. The availability of a one-pill regimen of this kind is described as a "critical tool" for public health efforts. This is viewed as vital to lessen the impact of the infection for people and to prevent the spread of extremely resistant gonorrhoea globally.